Message Font: Serif | Sans-Serif
 
No. of Recommendations: 2
I thought that EXEL was getting a little ahead of itself at $8, but I'm not one to complain. It's gone up and down quite a bit over the years and I've bought on a couple of the dips, including the last drop below $6 a month ago.

Yes, there is great potential here and it seems like while there are no drugs close to being released to market, EXEL has built great relationships and is working collaboratively with the big dogs. Things should get interesting in 2-5 years when the pipeline has matured and EXEL's research finally pays off. Investors and patients both win.

Cheers to the eradication of cancer.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement